MedTrace Logo

A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

NCT06549907 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-08-12

No results posted yet for this study

Summary

This study is a single-center prospective exploratory research, aiming to identify clinical characteristics and biomarkers associated with the therapeutic effects of dual PD1/PDL1 and CTLA4 blockade plus anti-angiogenic therapy and investigate MR image characteristics during treatment in patients with MSS metastatic colorectal cancer and MSI solid tumors resistant to PD-1/PD-L1 antibody monotherapy.

Conditions

  • MSS Metastatic Colorectal Cancers
  • MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy

Interventions

OTHER

Multi-omics testing

Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.

OTHER

MRI

MRI will be conducted to investigate image characteristics during treatment

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Jian Li · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-10
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06549907 on ClinicalTrials.gov